ASH 2021 | Novel treatment combinations in AML: what’s to come?
Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, shares his thoughts on how the acute myeloid leukemia (AML) treatment paradigm is likely to evolve in the coming years. Dr Röllig believes that the field will move towards the use of new combinations of novel agents, with each other as well as with standard chemotherapy. He also comments on the importance of continued advancement of measurable residual disease (MRD) measurement technologies in order to better monitor patients and individually tailor treatment regimens. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Transcript (edited for clarity)
I think the developments will on one hand go to more intensive treatments, regarding the combination of more than one novel agent with each other, and also with standard chemotherapy in order to target the AML cells from different directions. And in order, in that way, to be able to eradicate the AML stem cells or the last AML blast in a larger proportion of patients.
On the other hand, I think, and I hope that the technology of MRD measurements will get more standardized and more sophisticated so that we will be able to monitor our patients and individually tailor the treatment of our patient, even de-escalate treatment in some patients based on their individual responsiveness to chemotherapy...
I think the developments will on one hand go to more intensive treatments, regarding the combination of more than one novel agent with each other, and also with standard chemotherapy in order to target the AML cells from different directions. And in order, in that way, to be able to eradicate the AML stem cells or the last AML blast in a larger proportion of patients.
On the other hand, I think, and I hope that the technology of MRD measurements will get more standardized and more sophisticated so that we will be able to monitor our patients and individually tailor the treatment of our patient, even de-escalate treatment in some patients based on their individual responsiveness to chemotherapy. So these two directions are most likely to characterize the further or the future treatment of AML.
Read more...
